The non-invasive test, Harmony Prenatal, uses the company’s proprietary technology to perform a directed analysis of cell-free DNA (cfDNA), collected from blood of mother and fetus.

The trials including multicenter, prospective non-invasive chromosomal evaluation (NICE) study, which enrolled Pregnant women at gestational age 10 weeks or later, were designed to detect Fetal Trisomy 21 and Trisomy 18.

Other trial examines possible clinical factors that might influence the fetal fraction of cfDNA in maternal plasma, a determinant to detect trisomy.

The company said the comparative analysis showed no difference in fetal cfDNA levels between high- and low-risk pregnant women providing support that the test’s performance will be just as robust in a general pregnancy population.